The Next platform will analyze clinical data from mBC patients treated in certain centers and notify clinicians when ESR1 testing is missing at disease progression.
Tempus AI,...
Exai to accelerate product development and partnering of its novel oncRNA- and generative AI-based liquid biopsy platform
Exai Bio, a next-generation oncRNA- and generative AI-based...
TSO 500 ctDNA Version 2 delivers faster turnaround time, greater analytical sensitivity, more streamlined workflow, further enabling precision medicine.
Illumina Inc., a global leader in...